Currently out of the existing stock ratings of Albert Lowe, 19 are a BUY (90.48%), 2 are a HOLD (9.52%).

Albert Lowe

Work Performance Price Targets & Ratings Chart

Analyst Albert Lowe, currently employed at CRAIG HALLUM, carries an average stock price target met ratio of 12.96% that have a potential upside of 10.57% achieved within 34 days.

Albert Lowe’s has documented 42 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RZLT, Rezolute at 29-Sep-2026.

Wall Street Analyst Albert Lowe

Analyst best performing recommendations are on RZLT (REZOLUTE).
The best stock recommendation documented was for RZLT (REZOLUTE) at 12/11/2025. The price target of $2 was fulfilled within 5 days with a profit of $0.6 (42.86%) receiving and performance score of 85.71.

Average potential price target upside

ATOS Atossa Genetics LCTX Lineage Cell Therapeutics NGNE Neurogene PMVP Pmv Pharmaceuticals SABS SAB Biotherapeutics SKYE Skye Bioscience CRDF Cardiff Oncology RZLT Rezolute

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 17-Sep-2020

$24

27 days ago
(01-Oct-2026)

8/13 (61.54%)

$19.06 (385.83%)

190

Buy Since 12-Feb-2024

$25

$23.12 (1229.79%)

$7

7 months 2 days ago
(26-Mar-2026)

14/15 (93.33%)

$20.29 (430.79%)

444

Buy Since 05-Jun-2025

$10

$7.4 (284.62%)

$4.05

8 months 16 days ago
(12-Feb-2026)

1/2 (50%)

$6.06 (153.81%)

251

Buy Since 08-Sep-2023

2 years 4 months 8 days ago
(20-Jun-2024)

1/1 (100%)

$-7.5 (-60.00%)

885

Buy Since 11-Oct-2018

$105

$102.4 (3938.46%)

$120

5 years 4 months 18 days ago
(10-Jun-2021)

3/4 (75%)

$43.95 (71.99%)

170

Show more analysts

Please expand the browser size to see the chart

Which stock is Albert Lowe most bullish on?

Potential upside of $41.45 has been obtained for NGNE (NEUROGENE)

Which stock is Albert Lowe most reserved on?

Potential downside of $0.92 has been obtained for CRDF (CARDIFF ONCOLOGY)

What Year was the first public recommendation made by Albert Lowe?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?